CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Recruiting· 19 target
Drug / intervention
Oncolytic Virus injection(IDOV-SAFETM)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06346041
NCT06346041Early Ph 1RecruitingUpdate OverdueUpdated 16mo ago · Completion was 6mo ago
Enrollment Stalled
Update Overdue
CompareCT.gov

A Phase I Study of Evaluating the Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·interventional·Posted Apr 3, 2024·Updated Feb 4, 2025

In Brief

A Early Phase 1 clinical trial evaluating Oncolytic Virus injection(IDOV-SAFETM) for Neoplasms. Currently recruiting, targeting 19 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-SAFETM in patients with advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesChina
Collaborators--

Timeline

Early Ph 1RecruitingOverdue
20252026
First PostedApr 3, 2024
Enrollment StartApr 12, 2024
Primary CompletionDec 31, 2025
Study CompletionApr 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1.7 yearsPosted 2.2 years ago

Interventions

Oncolytic Virus injection(IDOV-SAFETM)biological

Administered by intravenous injection as single agent.